phentolamine mesilate.txt

CLINICAL USE

Alpha-adrenoceptor blocker:Hypertensive crisis

DOSE IN NORMAL RENAL FUNCTION

2–5 mg repeated if necessary

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :377.5

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :54

%Excreted unchanged in urine &nbsp &nbsp : 13

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :No data

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :19 minutes/–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function Titrate dose to end point, i.e. lower BP

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unknown dialysability. Dose as in normal renal function

HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Anaesthetics: enhanced hypotensive effect

Antidepressants: additive hypotensive effect with MAOIs – avoid concomitant useAntihypertensives: enhanced hypotensive effect

Diuretics: enhanced hypotensive effect Linezolid: additive hypotensive effect

Moxisylyte: possibly severe postural hypotension

Vardenafil, sildenafil and tadalafil: enhanced hypotensive effect – avoid concomitant use

ADMINISTRATION

Reconstition

–

Route

Rate of Administration

–

Comments

–

OTHER INFORMATION

Titrate according to response

Tags: post-by-auto-php